+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

3D Cell Culture Market by Scaffold Format, Products, Application Areas, Purpose, and Key Geographical Regions: Industry Trends and Global Forecasts (3rd Edition), 2020-2030

  • ID: 5215165
  • Report
  • October 2020
  • Region: Global
  • 516 Pages
  • Roots Analysis

FEATURED COMPANIES

  • 101Bio
  • Biomaterials USA
  • EU-ToxRisk
  • Ionis Pharmaceuticals
  • OS Fund
  • Start-Up Chile

Overview

Animal cell cultures represent an integral part of the drug discovery and development process. The conventional 2 dimensional (2D) cell culturing format is still extensively used in early stage research and is instrumental in establishing initial proof-of-concept and validating mechanisms of action of pharmacological leads. However, over time, it has been demonstrated that such cultures are unable to accurately mimic the natural (in vivo) microenvironment. Moreover, cells cultured in monolayers are both morphologically and physiochemically different from their in vivo counterparts. This leads to differences in viability, growth rate, and function. Additionally, in adherent 2D culture systems, only 50% of the cell surface is exposed to the culture medium, which limits cell-to-cell and cell-to-medium interactions. In fact, a study reported that 95% of drugs that exhibited efficacy in 2D culture models failed in in vivo studies / human trials.  

Advances in biotechnology and materials science have enabled the development of a variety of 3-dimensional (3D) cell culture models. These systems have been demonstrated to be capable of more accurately simulating the natural tissue microenvironment and, thereby, can help overcome most of the challenges associated with 2D systems. In addition, there are certain complex 3D cell culture models that are likely to soon replace animal models. In other words, 3D cell cultures are able to better simulate the natural tissue microenvironments, thereby, serving as better in vivo models for use in experimental research, including drug discovery / toxicity testing, development of regenerative medicine, tissue engineering, and stem cell research. This is anticipated to drive the adoption of such solutions in the foreseen future. Moreover, in a recent study, perfused 3D culture systems were used to emulate human bronchial tissue and airway cells, in order to study infectious respiratory diseases. Further, 3D cell cultures and organoid-based screening systems are being developed to facilitate the study of the pathogenesis of the novel coronavirus and support ongoing drug development efforts on this front. Based on the current trend of use, we are led to believe that the COVID-19 pandemic is likely to result in an increased demand for such solutions, presenting lucrative opportunities for companies engaged in this domain. In this context, the overall 3D cell culture market is anticipated to witness substantial growth in the coming years.

Scope of the Report

The “3D Cell Culture Market by Scaffold Format (Scaffold Based and Scaffold Free System), Products (Hydrogel / Extracellular Matrix (ECM), 3D Bioreactor, 3D Petri Dish, Hanging Drop Plate, Microfluidic System, Micropatterned Surface, Microcarrier, Organ-on-Chip, Solid Scaffold, and Suspension System), Application Areas (Cancer Research, Drug Discovery and Toxicology, Stem Cell Research, Tissue Engineering and Regenerative Medicine), Purpose (Research Use and Therapeutic Use), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts (3rd Edition), 2020-2030” report features an extensive study of the current landscape and the likely future potential of 3D culture systems, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field.

In addition to other elements, the study includes:

  • An insightful assessment of the current market landscape of companies offering various 3D cell culture systems, along with information on a number of relevant parameters, such as year of establishment, size of employee base, geographical presence, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems). In addition, the chapter provides information related to the companies providing 3D culture related services, and associated reagents / consumables.
  • A detailed assessment of the overall landscape of scaffold based products, along with information on a number of relevant parameters, such as status of development (under development, developed not commercialized, and commercialized), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, and microcarriers), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. In addition, it presents details of the companies developing scaffold based products, highlighting year of establishment, size of employee base, and geographical presence.
  • A detailed assessment of the overall landscape of scaffold free products, along with information on a number of relevant parameters, such as status of development (under development, developed and not commercialized, and commercialized), type of product (attachment resistant surfaces, suspension systems and microfluidic systems), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based and polymer based), and material used for fabrication. In addition, it presents details of the companies developing scaffold free products, highlighting their year of establishment, size of employee base, and geographical presence.
  • A detailed assessment of the overall landscape of 3D bioreactors, along with information on a number of relevant parameters, such as type of 3D bioreactor (single-use, perfusion, fed-batch, and fixed-bed), and typical working volume. In addition, it presents details of the companies developing 3D bioreactors, highlighting year of establishment, size of employee base, and geographical presence.
  • An insightful analysis, highlighting the applications (cancer research, drug discovery and toxicology, stem cell research, tissue engineering and regenerative medicine) for which various 3D cell culture products are being developed / used.
  • Elaborate profiles of prominent players (shortlisted based on number of products being offered) that are engaged in the development of 3D cell culture products. Each company profile features a brief overview of the company, along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments, and an informed future outlook.
  • An analysis of the investments made in the period between 2015 and 2020, including seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, at various stages of development in small and mid-sized companies (established after 2005; with less than 200 employees) that are engaged in the development of 3D cell culture products.
  • An analysis of the various partnerships related to 3D cell culture products, which have been established between 2015 and 2020 (till September), based on several parameters, such as year of agreement, type of partnership (product development / commercialization agreements, product integration / utilization agreements, product licensing agreement, research and development agreements, distribution agreements, acquisitions, joint venture and other agreements), 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactor), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems), and most active players. It also provides the regional distribution of players involved in the collaborations.
  • An in-depth analysis of over 8,400 patents that have been filed / granted for 3D cell culture products, between 2015 and 2020, highlighting key trends associated with these patents, across type of patent, publication year, issuing authorities involved, CPC symbols, emerging focus areas, leading patent assignees (in terms of number of patents filed / granted), patent characteristics and geography. It also includes a detailed patent valuation analysis.
  • An in-depth discussion on the classification of 3D cell culture systems, categorized as scaffold based systems (hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers), scaffold free systems (attachment resistant surfaces, suspension systems and microfluidic systems) and 3D bioreactors.
  • An elaborate discussion on the methods used for fabrication of 3D matrices and scaffolds, highlighting the materials used, the process of fabrication, merits and demerits, and the applications of different fabrication methods.
  • Insights from an industry-wide survey, featuring inputs solicited from various experts who are directly / indirectly involved in the development of 3D cell culture products.
  • One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the 3D cell culture market. Based on multiple parameters, such as business segment, price of 3D cell culture products, and likely adoption of the 3D cell culture products, we have provided informed estimates on the likely evolution of the 3D cell culture systems market in the mid to long term, for the time period 2020-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] 3D cell culture scaffold (scaffold based systems, scaffold free systems, and 3D bioreactors), [B] type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems, and microfluidic systems), [C] area of application (cancer research, drug discovery / toxicity testing, stem cell research, and regenerative medicine / tissue engineering), [D] purpose (research use and therapeutic use), [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and RoW (Rest of the World)), and [F] leading product developers. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were also influenced by discussions held with senior stakeholders in the industry.

The report features detailed transcripts of interviews held with the following industry and non-industry players:

  • Brigitte Angres (Co-founder, Cellendes)
  • Bill Anderson (President and CEO, Synthecon)
  • Anonymous (President and CEO, Anonymous)
  • Anonymous (Co-founder and Vice President, Anonymous)
  • Scott Brush (Vice President, BRTI Life Sciences)
  • Malcolm Wilkinson (Managing Director, Kirkstall)
  • Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel)
  • Tanya Yankelevich (Director, Xylyx Bio)
  • Jens Kelm (Chief Scientific Officer, InSphero)
  • Walter Tinganelli (Group Leader, GSI)
  • Darlene Thieken (Project Manager, Nanofiber Solutions)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading industry players engaged in the development of 3D cell culture products?
  • What are the most popular 3D cell culture products?
  • What are the different applications for which 3D cell culture products are currently being developed?
  • What are the key factors that are likely to influence the evolution of this market?
  • What is the trend of capital investments in the 3D cell culture systems market?
  • Which partnership models are commonly adopted by stakeholders in this industry?
  • How is the COVID-19 pandemic likely to impact the 3D cell culture systems market?
  • How is the current and future opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to 3D cell culture systems market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 101Bio
  • Biomaterials USA
  • EU-ToxRisk
  • Ionis Pharmaceuticals
  • OS Fund
  • Start-Up Chile

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Cell Cultures
3.2.1. Primary Cell Cultures
3.2.2. Cell Lines
3.3. Morphology of Cells in Culture
3.4. Transition from 2D to 3D Cell Cultures
3.5. Overview of 3D Cell Culturing
3.5.1. Components of the Extracellular Matrix (ECM)
3.5.2. In Vitro Cell Culturing
3.5.3. Selection of Culture Format
3.6. Establishment and Maintenance of Cell Cultures
3.6.1. Isolating Cells from Tissues
3.6.2. Maintaining Cells in Culture
3.6.3. Sub-Culturing/Passaging
3.6.4. Cryogenic Storage
3.7. Requirements for Maintaining the Health of Cell Cultures
3.7.1. Safety Guidelines in a Cell Culture Facility
3.7.2. Cell Culture Health and Optimal Conditions for Growth
3.7.3. Concerns Related to Cross Contamination
3.7.4. Methods to Prevent Contamination
3.8. Need for 3D Cell Culture Systems
3.8.1. Model Systems
3.8.2. Drug Discovery and Preclinical Research
3.8.3. Cancer Research
3.8.4. Virology Research
3.8.5. Genetic Engineering and Gene Therapy Research
3.9. Advantages and Limitations of 3D Cell Culture Systems
3.10. Future Perspectives

4. CLASSIFICATION OF 3D CELL CULTURE SYSTEMS
4.1. 3D Cell Culture Classification
4.2. Scaffold based 3D Cell Cultures
4.2.1. Hydrogels/ECM Analogs
4.2.2. Solid Scaffolds
4.2.3. Micropatterned Surfaces
4.2.4. Microcarriers
4.3. Scaffold Free 3D Cell Cultures
4.3.1. Attachment Resistant Surfaces
4.3.2. Suspension Culture Systems
4.3.2.1. Hanging Drop Plates
4.3.2.2. Magnetic Levitation and 3D Bioprinting
4.3.3. Microfluidic Surfaces and Organs-on-Chips
4.3.4. 3D Bioreactors
4.4. Organoids

5. FABRICATION OF 3D MATRICES AND SCAFFOLDS
5.1. Chapter Overview
5.2. Methods for Fabricating Porous Scaffolds
5.2.1. Particulate Leaching
5.2.2. Solvent Casting
5.2.3. Emulsion Templating
5.2.4. Gas Foaming
5.2.5. Melt Molding
5.2.6. Microsphere Sintering
5.3. Methods for Fabricating Fibrous Scaffolds
5.3.1. Electrospinning
5.3.2. Phase Separation
5.3.3. Self-Assembly
5.3.4. Fiber Mesh and Fiber Bonding
5.4. Methods for Fabricating Hydrogels
5.4.1. Gelation
5.4.2. Solvent Casting and Particulate Leaching
5.4.3. Gas Foaming
5.4.4. Freeze Drying
5.4.5. Co-polymerization/Crosslinking Methods
5.4.6. Microfluidics
5.5. Methods for Fabricating Custom Scaffolds
5.5.1. Stereo-Lithography
5.5.2. 3D Bioprinting and Selective Laser Sintering (SLS)
5.5.3. Fused Deposition Modeling
5.5.4. Membrane Lamination
5.5.5. Rapid Prototyping/Solid Free-Form Technique
5.6. Methods for Fabricating Microspheres
5.6.1. Solvent Evaporation
5.6.2. Single and Double Emulsification
5.6.3. Particle Aggregation
5.7. Methods for Fabricating Native Scaffolds
5.7.1. Decellularization

6. 3D CELL CULTURE SYSTEMS: DEVELOPER LANDSCAPE
6.1. Chapter Overview
6.2. 3D Cell Culture System Developers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by 3D Cell Culture Format
6.2.5. Analysis by Type of Product
6.3. Heat Map Representation: Analysis by 3D Cell Culture Format and Location of Headquarters
6.4. Tree Map Representation: Analysis by Company Size and Type of Product
6.5. World Map Representation: Analysis by Location of Regional Headquarters
6.6. 3D Cell Cultures: List of Service Providers
6.7. 3D Cell Cultures: List of Assays, Kits and Reagents

7. MARKET LANDSCAPE: SCAFFOLD BASED PRODUCTS
7.1. Chapter Overview
7.2. Scaffold based Products: Overall Market Landscape
7.2.1. Analysis by Status of Development
7.2.2. Analysis by Type of Product
7.2.3. Analysis by Source of 3D Cultured Cells
7.2.4. Analysis by Method Used for Fabrication
7.2.5. Analysis by Material Used for Fabrication
7.2.6. Analysis by Type of Product and Source of 3D Cultured Cells
7.2.7. Analysis by Type of Product and Method Used for Fabrication
7.3. Scaffold Based Products: Developer Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.4. Leading Developers: Analysis by Number of Scaffold based Products
7.5. Tree Map Representation: Analysis by Type of Product and Company Size

8. MARKET LANDSCAPE: SCAFFOLD FREE PRODUCTS
8.1. Chapter Overview
8.2. Scaffold Free Products: Overall Market Landscape
8.2.1. Analysis by Status of Development
8.2.2. Analysis by Type of Product
8.2.3. Analysis by Source of 3D Cultured Cells
8.2.4. Analysis by Method Used for Fabrication
8.2.5. Analysis by Material Used for Fabrication
8.2.6. Analysis by Type of Product and Source of 3D Cultured Cells
8.2.7. Analysis by Type of Product and Method Used for Fabrication
8.3. Scaffold Free Products: Developer Landscape
8.3.1. Analysis by Year of Establishment
8.3.2. Analysis by Company Size
8.3.3. Analysis by Location of Headquarters
8.4. Leading Developers: Analysis by Number of Scaffold Free Products
8.5. Tree Map Representation: Analysis by Type of Product and Company Size

9. MARKET LANDSCAPE: 3D BIOREACTORS
9.1. Chapter Overview
9.2. 3D Bioreactors: Overall Market Landscape
9.2.1. Analysis by Type of 3D Bioreactor
9.2.2. Analysis by Working Volume
9.3. 3D Bioreactors: Developer Landscape
9.3.1. Analysis by Year of Establishment
9.3.2. Analysis by Company Size
9.3.3. Analysis by Location of Headquarters
9.4. Leading Developers: Analysis by Number of 3D Bioreactors

10. KEY APPLICATION AREAS
10.1. Chapter Overview
10.2. 3D Cell Culture Systems in Cancer Research
10.2.1. Need for 3D Culture Systems in Cancer Research
10.2.1.1. Improving Cancer Drug Screening with 3D Culture Systems
10.3. 3D Cell Culture Systems in Drug Discovery and Toxicity Screening
10.3.1. Drug Development Studies
10.3.2. Toxicity Screening
10.3.2.1. 3D Liver Models
10.3.2.2. Other 3D Models
10.4. 3D Cell Culture Systems in Stem Cell Research
10.4.1. Potential of 3D Culture Systems in Stem Cell Differentiation
10.4.2. In Vitro 3D Microenvironment to Induce Embryoid Body Formation
10.5. 3D Cell Cultures in Regenerative Medicine and Tissue Engineering
10.6. 3D Cell Culture Systems: Analysis by Key Application Areas
10.6.1. 3D Cell Culture Systems: Analysis by Key Application Areas and 3D Cell Culture Format
10.6.1.1. Scaffold based 3D Products: Analysis by Key Application Areas
10.6.1.2. Scaffold Free 3D Products: Analysis by Key Application Areas
10.6.1.3. 3D Bioreactors: Analysis by Key Application Areas

11. COMPANY PROFILES: SCAFFOLD BASED PRODUCTS (HYDROGEL/ECM DEVELOPERS)
11.1. Chapter Overview
11.1.1. 3D Biotek
11.1.1.1. Company Overview
11.1.1.2. Product Portfolio
11.1.1.3. Recent Developments and Future Outlook
11.1.2. Advanced BioMatrix
11.1.2.1. Company Overview
11.1.2.2. Product Portfolio
11.1.2.3. Recent Development and Future Outlook
11.1.3. Alphabioregen
11.1.3.1. Company Overview
11.1.3.2. Product Portfolio
11.1.3.3. Recent Developments and Future Outlook
11.1.4. Corning Life Sciences
11.1.4.1. Company Overview
11.1.4.2. Product Portfolio
11.1.4.3. Recent Developments and Future Outlook
11.1.5. REPROCELL
11.1.5.1. Company Overview
11.1.5.2. Product Portfolio
11.1.5.3. Recent Developments and Future Outlook

12. COMPANY PROFILES: SCAFFOLD FREE PRODUCTS (ORGAN-ON-CHIP DEVELOPERS)
12.1. Chapter Overview
12.1.1. CN Bio Innovations
12.1.1.1. Company Overview
12.1.1.2. Financial Information
12.1.1.3. Product Portfolio
12.1.1.4. Recent Developments and Future Outlook
12.1.2. Emulate
12.1.2.1. Company Overview
12.1.2.2. Financial Information
12.1.2.3. Product Portfolio
12.1.2.4. Recent Developments and Future Outlook
12.1.3. InSphero
12.1.3.1. Company Overview
12.1.3.2. Financial Information
12.1.3.3. Product Portfolio
12.1.3.4. Recent Developments and Future Outlook
12.1.4. Mimetas
12.1.4.1. Company Overview
12.1.4.2. Financial Information
12.1.4.3. Product Portfolio
12.1.4.4. Recent Developments and Future Outlook
12.1.5. TissUse
12.1.5.1. Company Overview
12.1.5.2. Product Portfolio
12.1.5.3. Recent Developments and Future Outlook

13. COMPANY PROFILES: 3D BIOREACTORS
13.1. Chapter Overview
13.2. BISS TGT
13.2.1. Company Overview
13.2.2. Product Portfolio
13.2.3. Recent Developments and Future Outlook
13.3. Celartia
13.3.1. Company Overview
13.3.2. Product Portfolio
13.3.3. Recent Developments and Future Outlook
13.4. Cell Culture
13.4.1. Company Overview
13.4.2. Product Portfolio
13.4.3. Recent Developments and Future Outlook
13.5. Cesco Bioengineering
13.5.1. Company Overview
13.5.2. Product Portfolio
13.5.3. Recent Developments and Future Outlook
13.6. Flexcell International
13.6.1. Company Overview
13.6.2. Product Portfolio
13.6.3. Recent Developments and Future Outlook
13.7. PBS Biotech
13.7.1. Company Overview
13.7.2. Product Portfolio
13.7.3. Recent Developments and Future Outlook
13.8. Synthecon
13.8.1. Company Overview
13.8.2. Product Portfolio
13.8.3. Recent Developments and Future Outlook

14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Types of Funding
14.3. 3D Cell Culture Systems: Funding and Investment Analysis
14.3.1. Analysis by Number of Funding Instances
14.3.2. Analysis by Amount Invested
14.3.3. Analysis by Type of Funding
14.3.4. Analysis by 3D Cell Culture Format
14.3.5. Analysis by Type of Product
14.3.6. Analysis by Geography
14.3.7. Most Active Players: Analysis by Number of Funding Instances
14.3.8. Most Active Players: Analysis by Amount of Funding
14.3.9. Most Active Investors: Analysis by Number of Instances
14.4 Concluding Remarks

15. PARTNERSHIPS AND COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models
15.3. 3D Cell Culture Systems: Recent Partnerships and Collaborations
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.2.1. Analysis by Year of Partnership and Type of Partnership
15.3.2.2. Analysis by Company Size and Type of Partnership
15.3.3. Analysis by Type of Partner
15.3.3.1. Analysis by Year of Partnership and Type of Partner
15.3.3.2. Analysis by Type of Partnership and Type of Partner
15.3.4. Analysis by 3D Cell Culture Format
15.3.4.1. Analysis by Year of Partnership and 3D Cell Culture Format
15.3.4.2. Analysis by Type of Partnership and 3D Cell Culture Format
15.3.5. Analysis by Type of Product
15.3.5.1. Analysis by Year of Partnership and Type of Product
15.3.5.2. Analysis by Type of Partnership and Type of Product
15.3.6. Most Active Players: Analysis by Number of Partnerships
15.3.7. Regional Analysis
15.3.8. Intercontinental and Intracontinental Agreements

16. PATENT ANALYSIS
16.1. Chapter Overview
16.2. Scope and Methodology
16.3. 3D Cell Culture Systems: Patent Analysis
16.3.1. Analysis by Type of Patent
16.3.2. Analysis by Publication Year
16.3.3. Analysis by Issuing Authority
16.3.4. Analysis by CPC Symbols
16.3.5. Emerging Focus Area
16.3.6. Leading Players: Analysis by Number of Patents
16.4. 3D Cell Culture Systems: Patent Valuation Analysis
16.5. Leading Patents: Analysis by Number of Citations

17. MARKET FORECAST
17.1. Chapter Overview
17.2. Forecast Methodology and Key Assumptions
17.3. Impact of COVID-19 Pandemic on Global 3D Cell Culture Market
17.4. Global 3D Cell Culture Market, 2020-2030
17.5. Global 3D Cell Culture Market: Distribution by Business Segment
17.5.1. 3D Cell Culture Systems Market, 2020-2030
17.5.2. 3D Cell Culture Consumables Market, 2020-2030
17.5.3. 3D Cell Culture Services Market, 2020-2030
17.6. Global 3D Cell Culture Systems Market: Distribution by 3D Cell Culture Format
17.6.1. 3D Cell Culture Systems Market for Scaffold based Products, 2020-2030
17.6.2. 3D Cell Culture Systems Market for Scaffold Free Products, 2020-2030
17.6.3. 3D Cell Culture Systems Market for 3D Bioreactors, 2020-2030
17.7. Global 3D Cell Culture Systems Market: Distribution by Type of Product
17.7.1. 3D Cell Culture Systems Market for Attachment Resistant Surfaces, 2020-2030
17.7.2. 3D Cell Culture Systems Market for Hydrogels/ECMs, 2020-2030
17.7.3 3D Cell Culture Systems Market for Micropatterned Surface, 2020-2030
17.7.4. 3D Cell Culture Systems Market for Microcarriers, 2020-2030
17.7.5. 3D Cell Culture Systems Market for Microfluidic Systems, 2020-2030
17.7.6. 3D Cell Culture Systems Market for Solid Scaffolds, 2020-2030
17.7.7. 3D Cell Culture Systems Market for Suspension Culture Systems, 2020-2030
17.8. Global 3D Cell Culture Systems Market: Distribution by Area of Application
17.8.1. 3D Cell Culture Systems Market for Cancer Research, 2020-2030
17.8.2 3D Cell Culture Systems Market for Drug Discovery and Toxicity Testing, 2020-2030
17.8.3. 3D Cell Culture Systems Market for Stem Cell Research, 2020-2030
17.8.4. 3D Cell Culture Systems Market for Regenerative Medicine and Tissue Engineering, 2020-2030
17.9. Global 3D Cell Culture Systems Market: Distribution by Purpose
17.9.1. 3D Cell Culture Systems Market for Research Use, 2020-2030
17.9.2 3D Cell Culture Systems Market for Therapeutic Use, 2020-2030
17.10. Global 3D Cell Culture Systems Market: Distribution by Geography
17.10.1. 3D Cell Culture Systems Market in North America, 2020-2030
17.10.2 3D Cell Culture Systems Market in Europe, 2020-2030
17.10.3. 3D Cell Culture Systems Market in Asia-Pacific, 2020-2030
17.10.4. 3D Cell Culture Systems Market in Latin America, 2020-2030
17.10.4. 3D Cell Culture Systems Market in Middle East and North Africa (MENA), 2020-2030
17.10.5. 3D Cell Culture Systems Market in Rest of the World, 2020-2030
17.11. Global 3D Cell Culture Systems Market: Distribution by Leading Players, 2020
17.12. Concluding Remarks

18. SURVEY ANALYSIS
18.1. Chapter Overview
18.2. Overview of Respondents
18.2.1. Designation of Respondents
18.3. Survey Insights
18.3.1. 3D Cell Culture Format
18.3.2. Type of Product(s) Offered
18.3.3. Status of Development of Product(s)
18.3.4. Source of 3D Cultured Cells
18.3.5. Method Used for Fabrication
18.3.6. Area(s) of Application
18.3.7. Services Offered for 3D Cell Cultures
18.3.8. Current and Future Market Opportunity

19. CONCLUSION

20. EXECUTIVE INSIGHTS
20.1. Chapter Overview
20.2. Cellendes
20.2.1. Company Snapshot
20.2.2. Interview Transcript: Brigitte Angres, Co-founder
20.3. Synthecon
20.3.1. Company Snapshot
20.3.2. Interview Transcript: Bill Anderson, President and CEO
20.4. Anonymous
20.4.1. Interview Transcript: Anonymous, President and CEO
20.5. Anonymous
20.5.1. Interview Transcript: Anonymous, Co-founder and Vice President
20.6. BRTI Life Sciences
20.6.1. Company Snapshot
20.6.2. Interview Transcript: Scott Brush, Vice President
20.7. Kirkstall
20.7.1. Company Snapshot
20.7.2. Interview Transcript: Malcolm Wilkinson, Managing Director
20.8. QGel
20.8.1. Company Snapshot
20.8.2. Interview Transcript: Ryder Clifford, Director and Simone Carlo Rizzi, Chief Scientific Officer
20.9. Xylyx Bio
20.9.1. Company Snapshot
20.9.2. Interview Transcript: Tanya Yankelevich, Director
20.10. InSphero
20.10.1. Company Snapshot
20.10.2. Interview Transcript: Jens Kelm, Chief Scientific Officer
20.11. GSI
20.11.1. Company Snapshot
20.11.2. Interview Transcript: Walter Tinganelli, Group Leader
20.12. Nanofiber Solutions
20.12.1. Company Snapshot
20.12.2. Interview Transcript: Darlene Thieken, Project Manager

21. APPENDIX I: TABULATED DATA

Note: Product cover images may vary from those shown
  • 101Bio
  • 3D Biomatrix
  • 3D Biotek
  • 3D Biotechnology Solutions
  • 3Dnamics
  • 4Dcell
  • 4titude
  • AbbVie Ventures
  • abc biopply
  • ABL Europe
  • Åbo Akademi University
  • Abstraction Ventures
  • Abzena
  • Accellta
  • Advanced BioMatrix
  • Advanced Regenerative Manufacturing Institute (ARMI)
  • Advanced Scientifics
  • Aetos Biologics
  • Afirmus Biosource
  • AGC
  • Agency for Science, Technology and Research (A*STAR)
  • AIM Biotech
  • Akero Therapeutics
  • Akron Biotech
  • Alector
  • Allevi
  • Alnylam Pharmaceuticals
  • American Laboratory Products
  • Alphabioregen
  • ALS Investment Fund
  • AlveoliX
  • AMS Biotechnology
  • AnaPath Services
  • Angel Investors
  • AngelMD
  • Angels 5K
  • Angels in MedCity
  • Angels Santé
  • Anthrogenesis
  • Aquitaine Science Transfert
  • Aquiti Gestion
  • AR Brown
  • ARL Design
  • ARTeSYN Biosolutions
  • AstraZeneca
  • Arizona State University
  • ATEL Ventures
  • Atera
  • Avantor
  • AxoSim
  • AXT
  • Axxicon
  • BASF
  • Bayer
  • B-CULTURE
  • BEOnChip
  • Bio-Byblos Biomedical
  • BioCat
  • BioConcept
  • BIOFABICS
  • Biogelx
  • Bioinspired Solutions
  • BioInvent International
  • BIOKÉ
  • BioLamina
  • Biomaterials USA
  • Biomerix
  • BiomimX
  • Biopredic International
  • BioTek Instruments
  • BiSS TGT
  • Bonus BioGroup
  • Bpifrance
  • BRAIN
  • BrainXell
  • Brammer Bio
  • Braveheart Investment Group
  • Bristol-Myers Squibb
  • Broad Institute
  • BRTI Life Sciences
  • Cambridge Bioscience
  • University of Cambridge
  • CarThera
  • Cedars-Sinai Medical Center
  • Celartia
  • Cell Applications
  • Cell Culture
  • CELLEC BIOTEK
  • Cellendes
  • Cellevate
  • CELLnTEC
  • CellSpring
  • CellSystems
  • CelVivo
  • Center for the Advancement of Science in Space
  • CESCO Bioengineering
  • Charles River Laboratories
  • Cherry Biotech
  • China Regenerative Medicine International
  • CITIC Securities
  • CN Bio Innovations
  • CN Innovations
  • Collagen Solutions
  • Comune di Milano
  • Corning Life Sciences
  • Cosmo Bio
  • CELLphenomics
  • Commonwealth Serum Laboratories
  • Curi Bio
  • Cyprio
  • Cyprotex
  • Cytiva
  • Danaher
  • Deepbridge Capital
  • Demcon
  • United States Department of Defense
  • Development Bank of Wales
  • DiPole Materials
  • Downing Ventures
  • Government of the Netherlands
  • Executive Agency for Small and Medium-sized Enterprises (EASME)
  • EBERS
  • Ectica Technologies
  • EDITHGEN
  • Electrospinning
  • Emulate
  • Enso Discoveries
  • Eppendorf
  • Esco Aster
  • Esperante
  • Ethicon
  • European Life Sciences Growth Fund (ELSGF)
  • European Commission
  • European Union
  • Eurostars
  • EU-ToxRisk
  • Eva Scientific
  • Evotec
  • faCellitate
  • Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
  • Fennik Life Sciences
  • Ferentis
  • FHNW University
  • FiberCell Systems
  • Fibralign
  • Finep
  • Finesse Solutions
  • Finovam Gestion
  • Flexcell International
  • Foundation for Technological Innovation
  • Founder
  • Founders Fund
  • Freeline
  • French Government
  • Frequency Therapeutics
  • FroggaBio
  • Fujifilm
  • FUJIFILM Wako Pure Chemical
  • Funakoshi
  • Gabriel Investments
  • Galapagos
  • GALIA Gestion
  • Gamma 3
  • Gelmetix
  • Gelomics
  • Gemini Bio
  • Gemstone Biotherapeutics
  • Genome Institute of Singapore
  • Georgia Research Alliance
  • Global Cell Solutions
  • Government of China
  • Great Stuff Ventures
  • GSI
  • GlaxoSmithKline
  • HµREL
  • Hamilton
  • Harvard Apparatus
  • Harvard College
  • HCS Pharma
  • Helvoet
  • Heraeus Medical
  • Hesperos
  • Histogenics
  • Human Models for Analysis of Pathways (HMAPs) Center
  • Hokkaido Soda
  • HP Wild Holding
  • Hubrecht Organoid Technology
  • Humanetics
  • Hyamedix
  • ibidi
  • IMSS-Gulf Bio Analytical
  • INITIO CELL
  • Innovate UK
  • Innovation Fund Denmark
  • Inova Health System
  • inRegen
  • InSphero
  • Invitrocue
  • InvivoSciences
  • Ionis Pharmaceuticals
  • Irdi Soridec Gestion
  • Janssen Biotech
  • Japan Vilene Company
  • Jellagen Marine Biotechnologies
  • Johns Hopkins University
  • JRI Orthopaedics
  • Kero
  • Kim & Friends
  • Kirkstall
  • KIYATEC
  • KOKEN
  • Koninklijke Nederlandse Akademie Van Wetenschappen
  • Kuraray
  • LabCorp
  • Laconia
  • LAMBDA Laboratory Instruments
  • Lantern Pharma
  • Lawrence J. Ellison Institute for Transformative Medicine
  • LBA Healthcare Management
  • Lena Biosciences
  • LFB Biomanufacturing
  • Life Technologies
  • Lifecore Biomedical
  • LifeNet Health
  • Laboratory for Integrated Micro Mechatronic Systems
  • Lineage Cell Therapeutics
  • Locate Bio
  • London School of Hygiene & Tropical Medicine
  • Lonza
  • Lund University
  • LuoLabs
  • Manchester BIOGEL
  • University of Mannheim
  • Maryland Momentum Fund
  • Massachusetts Institute of Technology
  • MassChallenge
  • MatTek Life Sciences
  • MBL International
  • GlassWall Syndicate
  • Menicon Life Science
  • Merck Accelerator
  • Merck Millipore
  • Michael J. Fox Foundation
  • Michigan Technological University
  • Micronit
  • MicroTissues
  • Midven
  • MIMETAS
  • Minerva Business Angel Network
  • Molecular Devices
  • Maryland Stem Cell Research Fund (MSCRF)
  • MTTlab
  • Nanobiose
  • Nano Dimension
  • Nanofiber Solutions
  • Nanogaia
  • National Aeronautics and Space Administration
  • National Center for Advancing Translational Sciences
  • National Institute of Health
  • National Institute on Aging
  • National Institutes for Food and Drug Control
  • National Science Foundation
  • National University Hospital
  • National University of Singapore
  • National Centre for the Replacement, Refinement and Reduction of Animals in Research
  • Neuromics
  • New Orleans BioFund
  • Newable Private Investing
  • Nexcelom Bioscience
  • Nord France Amorquage
  • Invest Northern Ireland
  • Northwick Park Institute for Medical Research
  • Nortis
  • Nova Biomedical
  • Novartis Venture Fund
  • Noviocell
  • Nucleus Biologics
  • NYU Winthrop Hospital
  • Olaregen Therapeutix
  • OMNI Life Science
  • Oregon Health & Science University
  • Organovo
  • Orthomimetics
  • OS Fund
  • Oxford MEStar
  • Pairnomix
  • Pall Corporation
  • Path BioAnalytics
  • PBS Biotech
  • Peak Capital Advisors
  • Pelo Biotech
  • Pensees
  • PepGel
  • Percell Biolytica
  • PerkinElmer
  • Pfizer
  • PHI
  • Pitch@Palace
  • PL BioScience
  • Plasticell
  • Pluristem Therapeutics
  • Portugal Ventures
  • Precision Biologics
  • Premedical Laboratories
  • Primorigen Biosciences
  • Principia SGR
  • ProBio
  • ProBioGen
  • Prodizen
  • PromoCell
  • Protista International
  • QGel Bio
  • QIAGEN (Suzhou)
  • Quintech Life Sciences
  • PT Rajawali Medika Mandiri
  • RASA
  • React4life
  • Real Research
  • RealBio Technology
  • Regemat3D
  • Repligen
  • REPROCELL
  • Research Without Animal Experiment
  • Revivocell
  • Rigenerand
  • Roche
  • RoosterBio
  • Roswell Park Comprehensive Cancer Center
  • Sanofi Ventures
  • SARSTEDT
  • Sartorius
  • S-BIO
  • ScienCell
  • SciFi VC
  • SciKon Innovation
  • Scinus Cell Expansion
  • Scottish Investment Bank
  • Seres Therapeutics
  • Shanghai Cienle Medical Technology
  • Shanghai Institute of Materia Medica
  • Shanghai Institute of Biochemistry and Cell Biology
  • Siemens Technology
  • Sigma-Aldrich
  • SKE Research Equipment
  • SmiLe Incubator
  • SoloHill Engineering
  • Spheritech
  • Spiber Technologies
  • Start-Up Chile
  • State Key Laboratory of Experimental Hematology
  • StemCell Systems
  • STEMCELL Technologies
  • Stemmatters
  • StemoniX
  • StemTek Therapeutics
  • SUN bioscience
  • Commission for Technology and Innovation
  • Swiss Federal Laboratories for Materials Science and Technology
  • SyndicateRoom
  • Synthecon
  • SynVivo
  • TA Instruments
  • Takeda
  • Tantti Laboratory
  • tebu-bio
  • TEDCO
  • Terumo
  • Texas Tech University Health Sciences Center
  • Development Bank of Wales
  • Ministry of Higher Education, Research and Innovation (France)
  • The Idea Village
  • Institute for Molecular Medicine Finland
  • Mario Negri Institute for Pharmacological Research
  • University of Alberta
  • University of Bath
  • University of Brescia
  • University of Bristol
  • University of Manchester
  • University of Milan
  • University of Strathclyde
  • University of Zurich
  • TheWell Bioscience
  • Thermo Fisher Scientific
  • Tianjin Weikai Biological Engineering
  • Tissue Click
  • TissueLabs
  • TissUse
  • Tokyo Future Style
  • TPG
  • TreeFrog Therapeutics
  • Trevigen
  • Triumvirate Environmental
  • Technical University of Berlin
  • Twinhelix
  • UK Innovation & Science Seed Fund
  • Science and Technology Facilities Council (STFC)
  • UK Science and Technology Facilities Council
  • University of Genoa
  • University College London
  • University Hospital Zurich
  • Stanford University
  • University of Arkansas for Medical Sciences
  • University of California
  • University of Central Florida
  • University of Nottingham
  • The University of Sheffield
  • University of Washington School of Pharmacy
  • University of Zurich
  • UPM Biomedicals
  • U.S. Small Business Administration
  • UW Medicine
  • VA Portland Health Care System
  • Vanderbilt University
  • Venture Kick
  • VentureSouth
  • Venturecraft
  • Viscofan BioEngineering
  • Visikol
  • Vivo Biosciences
  • VWR
  • Wake Forest Institute for Regenerative Medicine
  • Women Who Tech
  • XAnge
  • Xenos
  • XP Biomed
  • Xylyx Bio
  • Zhejiang University
  • zPREDICTA
Note: Product cover images may vary from those shown

 

 

Loading
LOADING...

Adroll
adroll